Boster Immunoleader

antibody

Anti-CD134/OX40 Antibody

PA2136-2

100 ug/vial

200 USD

polyclonal

rabbit

Anti-CD134/OX40 Antibody

PA2136-2

Polyclonal

Rabbit IgG polyclonal antibody for Tumor necrosis factor receptor superfamily member 4(TNFRSF4) detection. Tested with WB in Mouse.

200 USD

Rabbit IgG

100 ug/vial

Lyophilized

No cross reactivity with other proteins.

Reacts with: mouse

WB

Concentration: 0.1-0.5μg/ml; Tested Species: Mouse

WB: The detection limit for TNFRSF4 is approximately 0.5ng/lane under reducing conditions. Tested Species: In-house tested species with positive results. Predicted Species: Species predicted to be fit for the product based on sequence similarities. Other applications have not been tested. Optimal dilutions should be determined by end users.

A synthetic peptide corresponding to a sequence at the N-terminus of mouse CD134(22-43aa ARRLNCVKHTYPSGHKCCRECQ).

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3.

Immunogen affinity purified.

Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

At -20˚C for one year. After reconstitution, at 4˚C for one month. It can also be aliquotted and stored frozen at -20˚C for a longer time. Avoid repeated freezing and thawing.

Boster provides a series of assays reacted with primary antibodies. Antibody can be supported by chemiluminescence kit EK1002 in WB.

Tumor necrosis factor receptor superfamily, member4, also known as ACT35 or CD134 is a cell surface glycoprotein that was discovered through the production of a monoclonal antibody raised against the HUT-102 cell line. It belongs to the tumor necrosis factor receptor superfamily. CD134 was mapped to 1p36 by fluorescence in situ hybridization. CD134 is the primary receptor for feline immunodeficiency virus. CD134 expression can promote viral binding and renders cells permissive for viral entry, productive infection, and syncytium formation. Stimulating the receptor can improve the response to a powerful virus vector and may be useful in vaccine development.

1. Bansal-Pakala, P., Jember, A. G.-H., Croft, M. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nature Med. 7: 907-912, 2001. 2. Humphreys, I. R., Walzl, G., Edwards, L., Rae, A., Hill, S., Hussell, T. A critical role for OX40 in T cell-mediated immunopathology during lung viral infection. J. Exp. Med. 198: 1237-1242, 2003. 3. Jember, A. G.-H., Zuberi, R., Liu, F.-T., Croft, M. Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40. J. Exp. Med. 193: 387-392, 2001. 4. Shimojima, M., Miyazawa, T., Ikeda, Y., McMonagle, E. L., Haining, H., Akashi, H., Takeuchi, Y., Hosie, M. J., Willett, B. J. Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science 303: 1192-1195, 2004.

TNFRSF4

Tumor necrosis factor receptor superfamily member 4

tumor necrosis factor receptor superfamily, member 4

ACT 35 antibody ACT35 antibody ACT35 antigen antibody ATC35 antigen antibody CD 134 antibody CD134 antibody CD134 antigen antibody Lymphoid activation antigene ACT35 antibody OX 40 antibody OX40 antibody OX40 antigen antibody OX40 cell surface antigen antibody OX40 homologue antibody OX40L receptor antibody TAX transcriptionally activated glycoprotein 1 receptor antibody TAX transcriptionally-activated glycoprotein 1 receptor antibody TNFRSF 4 antibody TNFRSF4 antibody TNR4_HUMAN antibody Tumor necrosis factor receptor superfamily member 4 antibody Txgp 1l antibody Txgp1 antibody Txgp1l antibody

P47741